Skip to main content
Amgen10-Q: Pricing pressure

ENBREL Net Selling Price Falls 15% Due to Medicare Part D Price Setting

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

Amgen reported a 15% decline in ENBREL net selling price and a 37% total sales decrease to $320 million for the quarter ended March 31, 2026, driven by Medicare Part D price setting and 340B Program mix.

Source

SEC EDGARApr 30, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

The decrease in ENBREL sales for the three months ended March 31, 2026 was primarily driven by unfavorable changes to estimated sales deductions of 18% and lower net selling price of 15% resulting from the impact of U.S. Medicare Part D price setting under the IRA, effective January 1, 2026, as well as an increased 340B Program mix.

sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Pricing pressure

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 30, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Percent
-15% (net selling price decline for ENBREL)

Details

CIK
318154
Accession number
0000318154-26-000057
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Cost optimization needed
Signal category
Market

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
pricingPressure

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/68ddf136-d50f-4515-ae87-76a047e1454b returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "68ddf136-d50f-4515-ae87-76a047e1454b",
  "signal_type": "sec-10q",
  "signal_subtype": "pricingPressure",
  "detected_at": "2026-11-09T06:24:49.379+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Amgen reported a 15% decline in ENBREL net selling price and a 37% total sales decrease to $320 million for the quarter ended March 31, 2026, driven by Medicare Part D price setting and 340B Program mix. This persistent pricing pressure may create opportunities for vendors offering market access, formulary optimization, and commercial analytics.",
    "metrics": {
      "pct": -0.15,
      "timeframe": "current_quarter",
      "pct_context": "net selling price decline for ENBREL",
      "dollar_context": "total ENBREL sales for the three months ended March 31, 2026"
    },
    "quarter": "Q1",
    "summary": "ENBREL Net Selling Price Falls 15% Due to Medicare Part D Price Setting",
    "excerpts": "The decrease in ENBREL sales for the three months ended March 31, 2026 was primarily driven by unfavorable changes to estimated sales deductions of 18% and lower net selling price of 15% resulting from the impact of U.S. Medicare Part D price setting under the IRA, effective January 1, 2026, as well as an increased 340B Program mix.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm",
    "filing_date": "2026-04-30",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Cost optimization needed",
    "signal_category": "market",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.